Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: A useful complement to stroke risk stratification schema

Chest

Volumn 130, Issue 5, 2006, Pages 1296-1299

  Kakar, Puneet ^a,b   Lane, Deirdre ^a,b   Lip, Gregory Y H ^a,b  

^a City Hospital ^*

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MODEL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 33751240118     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.5.1296     Document Type: Editorial

References (26)

1. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelgatran in patients with atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006; 118:311-333
2. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London, UK: Royal College of Physicians, 2006
3. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92:155-161
4. Lip GY, Lane D, van Walraven C, et al. The additive role of plasma von Willebrand factor levels to clinical factors for risk stratification in patients with atrial fibrillation. Stroke 2006; 37:2294-2300
5. Fang MC, Stafford RS, Ruskin JN, et al. National trends in anti-arrhythmic and anti-thrombotic medication use in atrial fibrillation. Arch Intern Med 2004; 164:55-60
6. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160:41-46
7. Lip GY, Zarifis J, Watson RD, et al. Physician variation in the management of patients with atrial fibrillation. Heart 1996; 75:200-205
8. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant- antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362-2367
9. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemostat 2001; 85:418-422
10. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med 1996; 156:409-416
11. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457
12. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study; Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med 1999; 159:1322-1328
13. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther 2004; 26:1470-1478
14. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141:745-752
15. Wehinger C, Stollberger C, Langer T, et al. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32:2246-2252
16. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-99
17. Wells PS, Forgie MA, Simms M, et al. The Outpatient Bleeding Risk Index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163:917-920
18. Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 2005; 20:1008-1013
19. Kuijer PMM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159:457-460
20. Shireman T, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130:1390-1396
21. Ryabov SI, Ryss ES, Prochukhanov RA, et al. Present-day concepts on gastric pathology in patients with chronic renal failure. Int Urol Nephrol 1980; 12:189-197
22. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35:134-148
23. Howitt A, Armstrong D. Implementing evidence-based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999; 318:1324-1327
24. Lane D, Lip GY. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment. Age Ageing 2005; 34:1-3
25. Lip GY, Kamath S, Jafri M, et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham atrial fibrillation project. Stroke 2002; 33:238-242
26. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme; The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006; 110:354-358